Insights On Upstream Manufacturing

  1. CHO Cell Line Characterization 7/20/2026

    Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

  2. Support A Biosimilar Program From Cell Line Development To Commercial 7/20/2026

    Explore end-to-end biosimilar development, combining proven commercial experience, integrated CMC expertise, and seamless GMP manufacturing to accelerate regulatory and commercial success.

  3. CLD Case Study: Complex Biologics – Bispecific Fusion Nanobody 7/17/2026

    See how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.

  4. Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies 7/15/2026

    Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality.

  5. Leveraging 3Rs For Superior Cell Line Characterization 7/13/2026

    Explore how non-animal methods, including next generation sequencing, are advancing biologics safety testing through the 3Rs while supporting faster adventitious virus testing and more.

  6. Production Of Disulfide-Rich Cow Knob Domain Antibodies 7/8/2026

    Discover how a microbial expression platform enabled high-titer production of disulfide-rich bovine knob domain antibodies with confirmed SARS-CoV-2 spike protein binding activity at 19 nM IC50.

  7. The Difference Between Batch, Fed-Batch, And Continuous Processes 7/6/2026

    Feeding strategy directly influences growth, yield, oxygen demand, and product quality. Choosing the right mode—batch, fed-batch, or continuous—helps balance productivity, control, and efficiency.

  8. A Practical Guide To Process Development From Shake Flask To Scale-Up 7/6/2026

    Scaling mammalian cell culture requires more than volume changes. Uncover why managing oxygen, pH, CO₂, and data consistency is critical to avoid failed transfers and ensure reproducible performance.

  9. Large-Scale Lentivirus Manufacturing With A Transfection Complex Stabilizer 7/6/2026

    De-risk large-scale lentivirus manufacturing by mastering transfection complex stability. Find out how to control particle aggregation, reduce fluid volumes to 2%, and minimize expensive GMP costs.

  10. Trusted Performance With A Plus: Seamless Transfer From R&D To Commercial 7/5/2026

    Bridge the gap between early R&D and commercial biomanufacturing. Learn how scalable control architectures, automated gassing strategies, and digital validation protocols streamline tech transfers.